Location History:
- AC Leiderdorp, NL (2020 - 2021)
- Leiderdorp, NL (2021)
Company Filing History:
Years Active: 2020-2021
Title: Jeffrey Colledge: Innovator in Pharmaceutical Composition
Introduction
Jeffrey Colledge is a notable inventor based in Leiderdorp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid dosage forms of bendamustine. With a total of 3 patents to his name, Colledge's work has the potential to impact the treatment of various medical conditions.
Latest Patents
Colledge's latest patents include innovative pharmaceutical compositions designed for oral administration. One of his notable inventions is a solid dosage form of bendamustine, which comprises bendamustine or a pharmaceutically acceptable ester, salt, or solvate as an active ingredient. This composition also includes at least one pharmaceutically acceptable excipient, specifically a saccharide, with a weight ratio of active ingredient to excipient ranging from 1:1 to 5. Another significant patent focuses on oral dosage forms of bendamustine, which demonstrate a dissolution rate of at least 60% in 20 minutes, 70% in 40 minutes, and 80% in 60 minutes. This formulation is intended for the treatment of various cancers, including chronic lymphocytic leukemia and breast cancer.
Career Highlights
Colledge is currently associated with Astellas Deutschland GmbH, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to improving drug formulations and enhancing patient outcomes.
Collaborations
Colledge collaborates with esteemed colleagues, including Margaretha Olthoff and Thomas Alfred Profitlich. Their combined expertise contributes to the advancement of pharmaceutical research and development.
Conclusion
Jeffrey Colledge's contributions to pharmaceutical innovations, particularly in the area of bendamustine formulations, highlight his role as a key inventor in the industry. His work not only showcases his inventive spirit but also holds promise for improving treatment options for patients facing serious medical conditions.